References
- Bethesda M D. Guidelines for the diagnosis, management of asthma. Expert Panel Report II. NIH Publication No. 97‐4051A, National Institutes of Health. 1997
- Global Initiative For Asthma. Revised Pocket Guide for Asthma Management and Prevention. NIH Publication No. 96‐3659B, 1998
- Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202–1218
- Celli B R, Snider G L, Heffner J. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77–S121
- Tweeddale P M, Alexander F, McHardy G JR. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42: 487–490, [PUBMED], [INFOTRIEVE]
- Burggraaf J, Westerndorp R G, In'tVeen J C, Schoemaker R C, Sterk P J, Cohen A F, Blauw G J. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; 56: 567–569, [PUBMED], [INFOTRIEVE], [CROSSREF]
- McFadden E R, Jr. Development, structure, and physiology in the normal lung and in asthma. Allergy: Principles and Practice5th ed., E Middleton, Jr, C E Reed, E F Ellis, et al. Mosby‐Year Book, Inc., St. Louis 1998; Vol. 1: 508–519
- Boggs P B, Bhat K D, Vekovius W A, Debo M S. The clinical significance of volume adjusted maximal mid expiratory flow (iso‐volume FEF25–75%) in assessing airway responsiveness to inhaled bronchodilator in asthmatics. Ann Allergy 1982; 48: 139–142, [PUBMED], [INFOTRIEVE]
- Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. Chest 1988; 93: 541–546, [PUBMED], [INFOTRIEVE]
- Vignola A M, Kips J, Bousquet J. Tissue remodeling as a feature of persistent asthma. J Allergy Clin Immunol 2000; 105: 1041–1053, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Papi A, Romagnoli N, Baraldo S, Braccioni F, Guzzinati I, Saetta M, Ciaccia A, Fabbri L M. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1773–1777, [PUBMED], [INFOTRIEVE]
- Siafakas N M, Vermeire P, Pride N B, Paoletti P, Gibson J, Howard P, Yernault J C, Decramer M, Higenbottam T, Rostma D S. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): the Europian Respiratory Society Task Force. Eur Respir J 1995; 8: 1398–1420, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anthonisen N R, Wright E C. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814–819, [PUBMED], [INFOTRIEVE]
- Callahan C M, Dittus R S, Katz B P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta‐analysis. Ann Intern Med 1991; 114: 216–223, [PUBMED], [INFOTRIEVE]
- Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77–S121